As with other chronic conditions, adherence to daily medications remains a challenge for
many individuals living with HIV due to structural, behavioral, and social barriers …

Highlights•Burden associated with chronic care management may undermine treatment
adherence.•Treatment fatigue may index when patient demands exceed coping …

Background Phase 3 clinical studies showed non-inferiority of long-acting intramuscular
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …

Background: A benchmark of near-perfect adherence (≥ 95%) to antiretroviral therapy
(ART) is often cited as necessary for HIV viral suppression. However, given newer, more …

Background Long-acting cabotegravir and rilpivirine administered monthly or every 2
months might address the challenges associated with daily oral antiretroviral therapy. The …

Background Antiretroviral agents with novel mechanisms and dosing intervals could expand
treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes …

People living with HIV (PLWH) have expressed concern about the life-long burden and
stigma associated with taking pills daily and can experience medication fatigue that might …

The role of microneedle array patches (MAPs) and, in particular, dissolving MAPs in
transdermal drug delivery has increased exponentially over the last decade. MAPs are able …

Finasteride (FND) is a competitive inhibitor of 5α-reductase, an enzyme involved in benign
prostatic hyperplasia (BPH) and androgenic alopecia. FND is administered in oral, often …

Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In
2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP) …